Characteristics and outcomes among patients with community-acquired respiratory virus infections during the first year after lung transplantation.

Tytuł:: Characteristics and outcomes among patients with community-acquired respiratory virus infections during the first year after lung transplantation.
Autorzy:: Mahan LD; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kanade R; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Mohanka MR; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bollineni S; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Joerns J; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kaza V; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Torres F; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
La Hoz RM; Division of Infectious Disease and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Banga A; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Źródło:: Clinical transplantation [Clin Transplant] 2021 Jan; Vol. 35 (1), pp. e14140. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Copenhagen : Munksgaard,
MeSH Terms:: Community-Acquired Infections/*epidemiology
Graft Rejection/*epidemiology
Lung Transplantation/*adverse effects
Respiratory Tract Infections/*epidemiology
Adolescent ; Adult ; Aged ; Community-Acquired Infections/diagnosis ; Community-Acquired Infections/virology ; Female ; Follow-Up Studies ; Graft Rejection/diagnosis ; Graft Rejection/virology ; Humans ; Male ; Middle Aged ; Prognosis ; Respiratory Tract Infections/diagnosis ; Respiratory Tract Infections/virology ; Retrospective Studies ; Risk Factors ; Texas/epidemiology ; Young Adult
References:: Lund LH, Edwards LB, Kucheryavaya AY, et al. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report-2013; focus theme: age. J Heart Lung Transplant. 2013;32:951-964.
Yusen RD, Edwards LB, Dipchand AI, et al. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016;35:1170-1184.
Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med. 2010;31:243-254.
Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation. 2009;87:1530-1537.
Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis. 2001;33:S58-S65.
Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol. 2007;45:2965-2970.
Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006;28:131-137.
Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559-566.
Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11:1071-1078.
Zeevi A, Lunz J. Cylex ImmuKnow cell function assay. Methods Mol Biol. 2013;1034:343-351.
Gauthier JM, Hachem RR, Kreisel D. Update on chronic lung allograft dysfunction. Curr Transplant Rep. 2016;3:185-191.
Allyn PR, Duffy EL, Humphries RM, et al. Graft loss and CLAD-onset is hastened by viral pneumonia after lung transplantation. Transplantation. 2016;100:2424-2431.
Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029-1036.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review. Ther Adv Respir Dis. 2016;10:235-255.
Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7:e47305.
Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM. 2010;103:379-385.
Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:587-595.
Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38:471-482.
Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62:313-319.
Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011;183:531-538.
Weigt SS, Derhovanessian A, Liao E, et al. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant. 2012;12:477-484.
Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34:958-962.
Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12:38-44.
Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35:213-221.
Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18:210-215.
Niggli F, Huber LC, Benden C, Schuurmans MM. Human metapneumovirus in lung transplant recipients: characteristics and outcomes. Infect Dis (Lond). 2016;48:852-856.
Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31:839-844.
Permpalung N, Thaniyavarn T, Saullo JL, et al. Oral and inhaled ribavirin treatment for respiratory syncytial virus infection in lung transplant recipients. Transplantation. 2020;104(6):1280-1286.
Glanville AR, Scott AI, Morton JM, et al. Intravenous Ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114-2119.
Pelaez A, Lyon GM, Force SD, et al. efficacy of oral Ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28:67-71.
Tantilipikorn P. The relationship between allergic rhinitis and viral infections. Curr Opin Otolaryngol Head Neck Surg. 2014;22:249-252.
Contributed Indexing:: Keywords: chronic lung allograft dysfunction; coronavirus infections; inhaled ribavirin; nasal corticosteroids
Entry Date(s):: Date Created: 20201104 Date Completed: 20210215 Latest Revision: 20210215
Update Code:: 20240105
DOI:: 10.1111/ctr.14140
PMID:: 33146445
: Czasopismo naukowe

Pełny tekst

Background: The current study describes the spectrum of community-acquired respiratory infections (CARV) during the first year after lung transplantation (LT). Additionally, we elucidate variables associated with CARV, management strategies utilized, and impact on early and late outcomes.
Methods: This was a retrospective study among patients transplanted between 2012 and 2015 (n = 255, mean age 55.6 ± 13.5 years, M: F 152:103). The diagnosis of CARV was based on the multiplex PCR on nasopharyngeal swab samples. Baseline characteristics, post-transplant variables, and outcomes were compared among patients with and without CARV.
Results: Eighty CARV infections developed among a quarter of the study group (n = 62, 24.3%). Rhinovirus/enterovirus was the most commonly isolated CARV (n = 24) followed by coronavirus (n = 17) and RSV (n = 9). A significant proportion of episodes (43.8%) required hospitalization. The use of nasal corticosteroids and left single LT was independently associated with an increased risk of CARV. CARV infections did not impact the lung functions during the first year or the CLAD-free survival at 3 years.
Conclusions: There is a significant burden of CARV infections during the first year after LT. The use of nasal corticosteroids may increase the risk of CARV infection. CARV infections did not impact outcomes.
(© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja